An observational study in Progressive Supranuclear Palsy, Parkinson Disease and MSA - Multiple System Atrophy, sponsored by Massachusetts General Hospital. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-07-29.
Sponsored by Massachusetts General Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Supranuclear Palsy, Progressive with a site in United States — 19 open to participants now, 25 under way, 1 of them phase 3. Supranuclear Palsy, Progressive · United States.
Among the 84 studies in Supranuclear Palsy, Progressive with a site in United States, this one is the 22nd largest by planned enrollment of the 31 observational ones that give a count, is one of 6 that started in 2026, is one of 31 observational ones, reaches primary completion later than 11 of the 24 other live ones, and was the 62nd registered.
171 studies on the registry are indexed under Supranuclear Palsy, Progressive; 51 are open to participants now.
Browse Supranuclear Palsy, Progressive studies →19 of the 84 studies in Supranuclear Palsy, Progressive with a site in United States are open now. Recruiting first, the newest first:
Prabesh Kanel · Sites in United States
Ages 45+
Adam Boxer · Sites in United States
Ages 41–86
Novartis Pharmaceuticals · Sites in United States, Australia, Belgium and 9 more countries
Ages 41–81
University of Pennsylvania · Sites in United States
Ages 18+ · Healthy volunteers
University of Pennsylvania · Sites in United States
Ages 40–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Supranuclear Palsy, Progressive studies recruiting now, 22 (58%) set no upper age limit and 2 (5%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 89 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 18 · Phase 3 5 · Phase 4 2
First in 1995; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 85 is below the median of 200 across 66 observational studies indexed under Supranuclear Palsy, Progressive.
Median enrollment 43 across the 52 interventional studies, 200 across the 31 observational. Of the 54 that completed or were terminated, 9 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 84 have an industry lead sponsor. The 10 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Massachusetts General Hospital has 4 studies filed under Supranuclear Palsy, Progressive — fewer than ten, so there is no comparison to draw.
8 of the studies in Supranuclear Palsy, Progressive with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03872102University of Texas Southwestern Medical CenterFacilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging | 2026-12-31 |
| NCT05913687University of FloridaAutomated Imaging Differentiation of Parkinsonism | 2027-03-31 |
| NCT04468932Oregon Health and Science UniversityTranscranial Magnetic Stimulation in Progressive Supranuclear Palsy | 2027-04 |
| NCT07863180Prabesh KanelTributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial | 2027-05 |
| NCT05459753University of MichiganCholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL) | 2027-06-30 |
Add all 8 to your calendar (.ics) → With an account.
Among the 84 studies in Supranuclear Palsy, Progressive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-arm, longitudinal, observational study on the use of wearable sensors and digital health technology to measure fall frequency and motor, speech, and cognitive function in patients with PSP over the course of approximately one year. Participants will perform supervised remote assessments monthly and in-person assessments approximately every 6 months.
The primary objective of this study is to determine the feasibility of using wearable sensors and digital health technology to remotely monitor patients with possible or probable PSP.
Secondary objectives are to measure PSP progression using sensor-derived motor and tablet-derived speech and cognitive measures.
In brief, approximately 85 individuals with possible or probable PSP, probable Parkinson's disease, possible or probable Multiple System Atrophy, and healthy controls, will be enrolled at 4-5 sites in the U.S. and followed for one year. During the monitoring period for PSP and MSA participants (1 year), a wearable pendant sensor (PAMSys, BioSensics) will be used to monitor falls and physical activity (step counts) of all participants during activities of daily living (ADL). Parkinson's and healthy control participants will be seen once at baseline only. On a monthly basis, participants will have televideo conferences with the sites to perform supervised gait and balance tasks while wearing 3 LEGSys (BioSensics) sensors. Using a study-supplied tablet, participants will also perform cognitive tests including fluency, color trails and go-no-go tapping tests. Participants will undergo more extensive testing every 3 months including the PSPRS, MoCA, quality of life questionnaires and functional rating scales which will be performed remotely (virtually). Approximately 6 months participants will undergo an in-person PSPRS (to coincide with their clinic appointments).
All participants with clinical diagnosis of possible or probable PSP, probable PD, or possible or probable MSA are eligible to participate in this study. Participants must be able to ambulate unassisted for 10 feet in order to perform gait and balance tests.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Primary feasibility outcome
Compliance will be calculated as the number of participants who wear their PAMSys pendant sensors at least 16 hours/day for at least 180 days and complete at least 80% of their scheduled monthly sensor and tablet derived motor, speech, and cognitive assessments through their 6 month visit.
Time frame: 12 months
Timed Up and Go (TUG)
The Timed Up and Go and other timed gait and balance tests will be performed while wearing LegSys sensors
Time frame: 12 months
PSPRS
The Progressive Supranuclear Palsy Rating Scale will be administered remotely or in-person every 3 months. The PSPRS is a 28 item scale with a total score of 0-100 where lower scores are less affected.
Time frame: 12 months
MoCA
The Montreal Cognitive Assessment and other cognitive tests will be performed remotely every 3 months. The MoCA is has a total of 30 points and greater than 26 is considered normal.
Time frame: 12 months
Cortical Basal ganglia Functional Scale (CBFS)
The Cortical Basal ganglia Functional Scale (CBFS) will be performed every 3 months remotely. The CBFS is a 31 item scale, with a total of 124 possible points, where a lower score is less affected.
Time frame: 12 months
PSP-QoL
The PSP Quality of Life scale will be performed every 3 months remotely. The PSP-QoL is a 45 item scale, with a possible scale of 0-100 with lower scores less affected.
Time frame: 12 months
Start is estimated for Sep 2026; primary completion for Dec 2028, 27 months later.
Of 37 observational studies under Supranuclear Palsy, Progressive, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 54. This study's planned 27 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Supranuclear Palsy, Progressive →
Massachusetts General Hospital →